Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 4/20 | 0.31 |
| ▸ | MMP13 | P45452 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9886034 | 0.86 | ALDH1A1 (0.39) | KDM4EKMT2AALDH1A1FFAR3MMP1 | |
| SCHEMBL15218845 | 0.86 | KDM4E (0.33) | KDM4EKMT2A | |
| SCHEMBL15221426 | 0.82 | CYP3A4 (0.36) | KDM4EKMT2AALDH1A1MMP1MMP13 | |
| SCHEMBL13062216 | 0.82 | CYP3A4 (0.36) | KDM4EKMT2AALDH1A1MMP1MMP13 | |
| SCHEMBL15219976 | 0.81 | — | — | |
| SCHEMBL14146934 | 0.80 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL13062219 | 0.78 | — | — | |
| SCHEMBL8199766 | 0.76 | SMN1; SMN2 (0.37) | KDM4EKMT2AALDH1A1MMP1MMP13 | |
| SCHEMBL11907527 | 0.75 | HTT (0.36) | ALDH1A1 | |
| SCHEMBL18122804 | 0.74 | KDM4E (0.59) | KDM4EKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719381-A1 | LIGAND-POLAR DRUG CONJUGATES | Tripartite Therapeutics Inc. (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | TRIPARTITE THERAPEUTICS INC. (TW) | 2025-01-30 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032635-A1 | LIGAND-POLAR DRUG CONJUGATES | CD274, SELPLG, PDCD1LG2 | KDM4E 4142/4885KMT2A 4242/4885ALDH1A1 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.